
Piscataway, NJ, February 12, 2024– Camber Pharmaceuticals is pleased to announce the addition of Paliperidone Extended-Release Tablets to its current portfolio.
Paliperidone Extended- Release Tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia, treatment of schizoaffective disorder as monotherapy, and as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone Extended- Release Tablets are available in 1.5, 3, 6, and 9 mg strengths in 30 count bottles.
To find out more about Paliperidone Extended- Release Tablets please visit www.camberpharma.com/paliperidone
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection